Merck KGaA signs AI-powered drug discovery deal with Vala worth more than $3 billion
Germany’s Merck KGaA has signed a major collaboration agreement with Boston-based Valo Health, using the biotech firm’s artificial intelligence-based drug discovery platform to advance research into Parkinson’s disease and related disorders. The deal could be worth more than $3 billion to Valu, the companies said Thursday.
Vallo said the deal includes upfront and milestone payments in excess of $3 billion, with additional royalties and research funding if development goals are met. The partnership focuses on identifying promising therapeutic molecules using Valo’s data-driven research tools, Nevs.Az conveys, quoting Reuters.
The move underscores Merck’s push to reinvigorate its pharmaceutical after failures in several late-stage trials, including the withdrawal of head and neck cancer drug Xevinapant last year. The society said the Valo partnership will help accelerate the development of its most promising candidates.
Merck, which also operates large businesses in semiconductor chemicals and biotech lab supplies, is looking for momentum after buying rare cancer specialist SpringWorks for $3.9 billion.
Founded in 2019, Valo uses artificial intelligence and big data sets, drawing on more than 17 million patient records and biological samples to support drug discovery while maintaining strict data privacy. The company is increasingly active in Parkinson’s disease research and in September received a grant from the Michael J. Focus on new treatment approaches.
Parkinson’s disease affects an estimated 1 million people in the United States, and despite decades of research, existing drugs primarily manage symptoms rather than halt disease progression—a persistent challenge that the new collaboration aims to address.
2025-11-20 11:49:00
